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Rhinovirus-(RV-) induced asthma exacerbations account for high asthma-related health costs and morbidity in Australia. The
cellular mechanism underlying this pathology is likely the result of RV-induced nuclear-factor-kappa-B-(NF-κB-) dependent
inﬂammation. NF-κB may also be important in RV replication as inhibition of NF-κB inhibits replication of other viruses such
as human immunodeﬁciency virus and cytomegalovirus. To establish the role of NF-κB inhibitors in RV-induced IL- 6 and IL-
8 and RV replication, we used pharmacological inhibitors of NF-κB, and steroids and/or β2 agonists were used for comparison.
PrimaryhumanlungﬁbroblastswereinfectedwithRV-16inthepresenceofNF-κBinhibitors:BAY-117085anddimethylfumarate;
β2 agonist: salmeterol; and/or corticosteroids: dexamethasone; ﬂuticasone. RV-induced IL-6 and IL-8 and RV replication were
assessed using ELISAs and virus titration assays. RV replicated and increased IL-6 and IL-8 release. Salmeterol increased, while
dexamethasone and ﬂuticasone decreased RV-induced IL-6 and IL-8 (P<0.05). The NF-κB inhibitor BAY-117085 inhibited only
RV-induced IL-6 (P<0.05) and dimethyl fumarate did not alter RV-induced IL-6 and IL-8. Dimethylfumarate increased RV
replication whilst other drugs did not alter RV replication. These data suggest that inhibition of NF-κB alone is unlikely to be an
eﬀective treatment compared to current asthma therapeutics.
1.Introduction
Asthma is a chronic inﬂammatory disease of the airways
characterised by reversible airﬂow obstruction, inﬂamma-
tion, and hyperresponsiveness to various allergic or non-
allergic stimuli such as house dust mites or exercise [1].
An asthma exacerbation is the increase in the duration
and severity of respiratory symptoms often resulting in
hospitalization. Respiratory viruses cause 85% of asthma
exacerbations, and 62% of all viral induced asthma exac-
erbations are caused by human rhinovirus (RV) [2]. Viral-
induced asthma exacerbations account for over 50% of the
total asthma-related health costs and also increase asthma
morbidity.
The bronchial epithelium has always been considered
as the primary site of RV infection; however, increasing in
vivo evidence shows that RV can also infect submucosal cells
such as ﬁbroblasts and airway smooth muscle (ASM) [3, 4].
In vitro studies have shown that transformed and primary
human airway cells infected with RV release a plethora of
proinﬂammatory cytokines, such as interleukin (IL)-6, IL-8,
and the antiviral cytokine: interferon (IFN)-λs[ 3, 5–7]. The
mechanism of this is most likely due to RV-activated nuclear
factor kappa B (NF-κB).
NF-κB is a transcription factor, implicated in the ex-
pression of over 100 proinﬂammatory genes which mostly
participate in the host immune response [2, 8]. NF-κBi s
exploited by many viruses such as RV and retroviruses to2 Journal of Allergy
promote their replication by preventing viral-induced apop-
tosis and evading the immune system [8, 9].
Previous studies have found that RV can activate NF-
κBv i aI κB kinase (IKK)-α/β or phosphorylation of IκBa n d
cause the upregulation of numerous cytokines [2, 10, 11].
Despite the vast array of asthma medication available, β2
agonists and corticosteroids remain the most eﬀective treat-
ments in asthma to control and prevent symptoms [12].
However their use does not prevent asthmatics from respi-
ratory viral infections or RV-induced asthma exacerbation
[13]. Therefore there is a need for speciﬁc treatment strat-
egies for RV-induced asthma exacerbation.
Studies have shown that inhibition of NF-κBr e d u c e s
viral-induced cytokine release and also inhibits replication
of human immunodeﬁciency virus (HIV) and human cyto-
megalovirus (HCMV) [14, 15]. However to date no research
has examined the eﬀect of inhibiting NF-κB on RV-induced
cytokine release and RV replication in airway cells. For this
reason, this study investigated if NF-κB inhibitors, either
alone or in combination with the currently used asthmatic
drugs, β2 agonists and corticosteroids, reduce both RV-
induced cytokine release and RV replication in human
primary airway ﬁbroblasts. This study may provide in vitro
data that may be beneﬁcial in determining a more adequate
treatment regimen for RV-induced asthma exacerbations.
2.MaterialsandMethods
2.1. Isolation and Culture of Human Fibroblasts. Primary
human airway ﬁbroblasts were obtained from macroscop-
ically healthy lung tissue. Lung tissue was obtained from
patients undergoing resections or transplantations (see
Table 1 for demographics).
Parenchymal tissue was washed in sterile Hanks balanced
saltsolution(TraceScientiﬁc,Melbourne,Australia),minced
and suspended in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) (Sigma-Aldrich, Castle Hill, Australia) supple-
mented with 10% (v/v) foetal bovine serum (FBS) (JRH Bio-
sciences, Melbourne, Australia), 20U/mL penicillin, 20g/mL
streptomycin, and 2.5g/mL amphotericin B (Invitrogen,
Mount Waverley, Australia) in 75cm2 tissue culture ﬂasks.
The cells were grown to conﬂuence, and ﬁbroblast character-
istics were conﬁrmed by normal ﬁbroblast growth patterns
and cell morphology as described previously by Ghildyal
et al. [7]. All experiments were carried out with ﬁbroblasts
between passages 2 and 8.
Ethical approval for all experiments involving the use of
human lung tissue was provided by The University of Sydney
Human Ethics Committee and the Sydney South West Area
Health Service, and written informed consent was obtained.
2.2. RV Propagation and Ultraviolet Inactivation of RV (UVi-
RV). M a j o rg r o u ph u m a nR Vs e r o t y p e - 1 6w a sp u r c h a s e d
from ATCC (Manassas, USA) and propagated in Ohio HeLa
cells as previously described by Papi and Johnston [16].
In some experiments RV was UV inactivated in 24 well
plates containing 200μL of RV/well at a distance of 5cm
from a 30W UV light source (germicidal lamp G30T8,
Table 1: Demographics of donors from whom ﬁbroblasts used in
this study were isolated.
Patient Disease Sex Age
(years)
1 Transposition of the great arteries M 39
2 Chronic obstructive pulmonary disease
(COPD) M5 6
3 No disease M 48
4 Idiopathic pulmonary ﬁbrosis (IPF) M 61
5 Emphysema M 63
6 Small cell carcinoma M 63
7 Lymphangioleiomyomatosis (LAM) F 51
8 Pulmonary ﬁbrosis M 53
9 Bronchiectasis M 53
10 Emphysema M 40
11 Non-small cell carcinoma M 77
12 Cystic Fibrosis M 45
13 Non Small Cell Carcinoma F 63
14 Non-small cell carcinoma F 79
15 Primary pulmonary hypertension F 36
16 Lymphangioleiomyomatosis (LAM) F 33
17 Emphysema F 56
18 Emphysema F 48
19 Melanoma M 63
20 Carcinoma M 59
21 Lesion F 58
22 Resection M 48
23 Carcinoma F 83
24 Idiopathic pulmonary ﬁbrosis (IPF) M 57
25 Carcinoma F 76
26 Emphysema F 50
27 Idiopathic pulmonary ﬁbrosis (IPF) M 56
28 Pulmonary ﬁbrosis M 68
29 Rejection:pneumonitis M 21
30 α1 antitrypsin deﬁciency M 55
31 Hypersensitive pneumonitis M 59
32 α1 antitrypsin deﬁciency M 42
33 Emphysema M 42
34 Bronchiectasis M 39
3 5 S m a l lc e l lC a r c i n o m a F 7 8
Sankyo Denki, Japan) for 15 minutes. UV inactivation was
established to be eﬀective by a RV titration assay and was
used as a noninfectious virus control.
2.3. Drug Concentrations. Dexamethasone, BAY-117085
(BAY), dimethyl fumarate (DMF) (Sigma-Aldrich), ﬂutica-
sone propionate, and salmeterol (GSK, Boronia, Australia)
were dissolved in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich) at 10−3 M and further diluted in 0.1% FBS/
antibiotics/DMEM to give ﬁnal experimental concentrationJournal of Allergy 3
ranges of 10
−12–10
−6 M and corresponding vehicle controls
0.001–0.1% DMSO. For drug combination experiments,
the lowest concentration of drug to produce an eﬀect was
used.
2.4. RV Infection of Primary Human Airway Fibroblasts. Fi-
broblasts were seeded at 3.2 × 104 cells/mL into 6 well plates
in 10% FBS/DMEM and grown for 3 days. Prior to RV
infection, a cell count was carried out to determine the
amount of RV (or UVi-RV) needed to infect at a multiplicity
of infection (MOI) of 0.1. The medium was then replaced
with 0.1% FBS/antibiotics/DMEM and or drug/vehicle and
incubated for 1 hour at 37◦C and 5% CO2. Some of the
wells were infected at an MOI of 0.1 with UVi-RV or
live RV respectively and left for 1 hour at 37◦Ca n d5 %
CO2. Plates were rocked every 15 minutes to disperse the
virus or contents. The medium was removed, the cells
were washed with the Hanks solution, and 2mL/well of
fresh sterile 0.1% FBS/antibiotics/DMEM or drug/vehicle
was added. The plates were then incubated at 37◦Ca n d5 %
CO2 over time, and supernatants were collected and stored
at −20◦C prior to analysis using ELISA and RV titration
assays.
2.5. RV Titration Assay. All viral concentrations were mea-
sured by a titration assay as outlined by Papi and Johnston
[16]. Brieﬂy, RV levels were determined by serially titrating
log-diluted concentrations of the cell-free supernatant in
quadruplicates on the Ohio HeLa cells. The Ohio HeLa cells
were seeded at a concentration of 2 × 104 cells/mL in 96
well plates (150μL/well) and then 50μL of supernatants with
RV or control medium was added to the wells. The plates
were rocked at 100rpm for 15 minutes at room temperature
before being cultured for 5 days at 37◦C and 5% CO2.A f t e r
5 days of culture, the cytopathic eﬀect (CPE) was assessed by
comparing the cells in the RV-infected wells to the control
wells. Viral concentration was determined using Karber’s
method as described previously [7]. The concentration of
RV-16 stock was determined to be 6.3 × 105 virions/mL.
2.6. ELISA. ELISA kits for IL-28A (interferon λ2), IL-29
(interferon λ1), IL-6, and IL-8 were purchased from R&D
Systems (Minneapolis, USA) and BD Biosciences (North
Ryde, Australia), respectively. ELISAs were carried out ac-
cording to the manufacturer’s instructions. The detection
limits of these assays were 62.5pg/mL (IL-28A), 31.2pg/mL
(IL-29), 7.8pg/mL (IL-6), and 15.6pg/mL (IL-8).
2.7. Statistical Analysis. Since there were no diﬀerential
responses to RV in cells from patients with diﬀerent diag-
noses,resultswerepooledandanalysedtogetherinthisstudy.
All data were veriﬁed for normality and values presented
as mean ± SEM. When results were nonparametrically dis-
tributed, the dataset was log transformed prior to statistical
analysis using GraphPad Prism Version 5 software (Calif,
USA). ELISA and RV titration results were analysed by
either a 1-or 2-way analysis of variance (ANOVA) with the
Dunnett or Bonferroni posttest comparisons where appro-
priate and indicated. Statistical signiﬁcance was shown when
P ≤ 0.05.
3. Results
3.1. RV Infects Human Primary Airway Fibroblasts and Stim-
ulates IL-6 and IL-8 Production but Not IL-28A (Interferon
λ2)a n dI L - 2 9( I n t e r f e r o nλ1). To determine if RV induced
IL-6 and IL-8 release and replicated in ﬁbroblasts, tissue
culture medium of infected ﬁbroblasts was assessed using RV
titration assay and ELISA at 0, 3, 6, 24, 48, and 72 hours post
infection.
RV replicated in ﬁbroblasts and was maximal 24h post
infection when compared to 0 hours (P<0.0001; n = 5;
Figure 1(a)).Therewasnostatisticalsigniﬁcancebetweenthe
number of virions at 24 and 48 hours post infection.
A sc a nb es e e ni nF i g u r e s1(b) and 1(c), RV-induced IL-6
and IL-8 were maximal at 48 hours, compared to respective
constitutive release (n = 5, P<0.0001). No induction was
observed with UVi-RV.
RV-16 did not induce IL-28A and IL-29 from human
primary airway ﬁbroblasts (n = 5, data not shown).
3.2. Corticosteroids Suppress and β2 Agonists Increase Primary
Airway Fibroblast Responses to RV Infection. To determine if
the corticosteroids dexamethasone and ﬂuticasone and the
β2 agonist salmeterol could inhibit RV-induced IL-6 and IL-
8 and RV replication, tissue culture medium from ﬁbroblasts
pretreated with drug for 1 hour and then infected with RV
was analysed by ELISA after 48 hours and RV titration 24
hours post infection.
As before RV induced IL-6 and IL-8 (Figure 2, n = 7–9,
P<0.05). Dexamethasone signiﬁcantly inhibited both RV-
inducedIL-6andIL-8atconcentrationsgreaterthan10−10 M
and 10−8 M, respectively (Figures 2(a) and 2(b), n = 7, P<
0.05). Fluticasone signiﬁcantly inhibited both RV-induced
cytokines at all concentrations tested 10
−10–10
−8 M (Figures
2(c) and 2(d), n = 7, P<0.05). Dexamethasone did
not inhibit the constitutive release of IL-6 and IL-8 at the
concentrations tested (n = 7, P>0.05), while ﬂuticasone
inhibited the constitutive release of IL-6 and IL-8 at all
concentrations (10
−10–10
−8 M; n = 7, P<0.05) (Table 2).
However salmeterol further increased RV-induced IL-6 and
IL-8, almost 2-fold more than RV control at concentrations
10−8 to 10−7 M (Figures 2(e) and 2(f), n = 9, P<0.05).
Salmeterol signiﬁcantly induced the constitutive release of
IL-6 at 10−8 Ma n dI L - 8a t1 0 −8 and 10−7 M, (Table 2, n =
9, P<0.05). The highest concentration of vehicle used had
no signiﬁcant eﬀect on the level of IL-6 and IL-8 induction.
Dexamethasone, ﬂuticasone, and salmeterol did not alter RV
replication (data not shown).
3.3. NF-κB Inhibitors Increase RV Replication and Suppress
RV-Induced IL-6 in Primary Airway Fibroblasts. To deter-
mine if the NF-κB inhibitors, BAY and DMF could inhibit
RV-induced IL-6 and IL-8 and RV replication, tissue culture
medium from ﬁbroblasts pretreated with drugs and then4 Journal of Allergy
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Figure 1: (a) Time course of RV replication. Concentration is of RV from infected ﬁbroblasts (MOI = 0.1) at 0, 3, 6, 24, 48 and 72
hours post infection were measured by RV titration. RV concentration was compared with each time point post infection using a 1-way
ANOVA (n = 5). (b,c) Time course of RV-induced IL-6 and IL-8. Concentration of (b) IL-6 and (c) IL-8 release from noninfected ﬁbroblast
(constitutive release) or UVi-RV-(UVi-) or RV-16-(RV-) infected ﬁbroblasts (MOI = 0.1) at 0, 3, 6, 24, 48 and 72 hours post infection were
measured by ELISA. RV-induced IL-6 and IL-8 at 48, and 72 hours post infection compared to control and UVi (2-way ANOVA, n = 5). All
data are presented as mean ± SEM. Signiﬁcance of comparisons is represented as ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.0001.
infected with RV was analysed by ELISA after 48 hours and
RV titration 24 hours post infection.
As before RV induced IL-6 and IL-8 (Figure 3, P<
0.05, n = 9-10). BAY signiﬁcantly inhibited the constitutive
release (Table 3) and RV-induced IL-6 at 10−6 Mb u tf a i l e d
to inhibit IL-8 at the concentrations used (Figures 3(a) and
3(b), n = 10, P<0.05). DMF had no eﬀect on RV-
induced IL-6 and IL-8 (Figures 3(c) and 3(d),D M F :n = 9).
Interestingly, DMF increased the constitutive release of IL-
8( Table 3, n = 9, P<0.05). The highest concentration of
vehicle used to dissolve BAY and DMF had no eﬀect on the
level of IL-6 and IL-8 induction.
BAY had no eﬀect on RV replication (n = 10, data
not shown). DMF, however, signiﬁcantly increased RV
replication at 10
−8–10
−7 M( Figure 4, n = 14, P<0.05).
The highest concentration of vehicle used to dissolve BAY
a n dD M Fh a dn oe ﬀect on RV replication.
3.4.AdditionofaNF-κBInhibitortotheCombinationTherapy
of a Corticosteroid and β2 Agonist Inhibits RV-Induced IL-6
in Primary Airway Fibroblasts. Since BAY was able to inhibit
RV-induced IL-6 release but not IL-8, BAY at 10−6Mw a s
combined with the lowest concentration of salmeterol (Sal)
(10−8 M) and ﬂuticasone (Flut) (10−10 M) which caused an
eﬀect, to examine if the combination could inhibit RV-
induced IL-6 and RV replication.
As before RV induced IL-6 (Figure 5, n = 4, P<0.05).
Salmeterol and ﬂuticasone in combination (Sal + Flut)
inhibited RV-induced IL-6 by 80%, and in the additional
presence of the NF-κB inhibitor BAY (Sal + Flut + BAY),
total inhibition occurred (100%) (Figure 5, n = 4, P<
0.01). However RV replication was not altered (n = 4, data
not shown). The highest concentration of vehicle used to
d i s s o l v e S a l+F l u t a n d S a l+F l u t+B A Y h a d n o e ﬀect
on IL-8 induction or RV replication (data not shown).Journal of Allergy 5
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Figure 2: (a–f) Eﬀect of dexamethasone (Dex), ﬂuticasone (Flut) and salmeterol (Sal) on RV-induced IL-6 and IL-8. Concentration of IL-6
andIL-8release fromnoninfectedﬁbroblasts(constitutiverelease),UVi-RV-(UVi-)orRV-16-infectedﬁbroblasts(RV)(MOI = 0.1),highest
concentration of vehicle (Dex & Sal: 0.1% DMSO; Flut: 0.001% DMSO) and RV infected ﬁbroblasts in the presence of Dex: 10
−12–10
−7 M
(n = 7), Flut: 10
−10–10
−8 M( n = 7) and Sal: 10
−8–10
−6 M( n = 9) were measured 48hrs post infection by ELISA. All IL-6 and IL-8
concentrations were compared to their respective RV-induced values (in the absence of drug and vehicle), using a 1-way ANOVA. All data
are presented as mean ±SEM. Signiﬁcance is represented as ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.0001.
4. Discussion
This study examined the eﬀects of current asthma medica-
tions such as corticosteroids and β2 agonists and potential
novel treatments such as NF-κB inhibitors, as well as their
combination in the treatment of RV-induced inﬂammation
and RV replication in airway ﬁbroblasts. The study con-
ﬁrmed that RV was able to infect and replicate in primary
airway ﬁbroblasts and that RV can induce proinﬂammatory
cytokines IL-6 and IL-8 but not IL-28A and IL-29 from
primary airway ﬁbroblasts. Therefore this in vitro model
simulates a possible underlying inﬂammatory scenario expe-
rienced during RV-induced asthma exacerbations in vivo.
No induction was observed with UVi-RV, and thus UVi-RV-
treated ﬁbroblasts were not studied further.
Interferons are cytokines which are released by cells
in response to pathogens to trigger protective defences of
the immune system, and it has been shown that asthmatic
patients maybemoresusceptibletoRVinfectionduetotheir
deﬁcient interferon β and λ responses in bronchial epithelial
cells [5, 17]. In our study we measured both IL-28A and6 Journal of Allergy
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Table 3: Eﬀects of BAY and DMF on the constitutive release of IL-6 and IL-8.
Constitutive release [pg/mL] 10x [M]
Drug Cytokine Noninfected Vehicle −8 −7 −6
BAY IL-6 5159 ±1531 5005 ±1631 5826 ±1879 4790 ±1530 2556 ±803.9∗∗
IL-8 5598 ±2109 4573 ±1947 4442 ±1761 3958 ±1719 3423 ±1334
DMF IL-6 5743 ±1001 5970 ±1226 5907 ±1086 5998 ±1122 5937 ±984.7
IL-8 6151 ±1055 7296 ±1803 7180 ±1664 7151 ±1756 8329 ±1780∗
Values are means ±SEM.
∗P<0.05, and ∗∗∗P<0.0001.
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Figure 3: (a–d) Eﬀect of BAY and DMF on RV-induced IL-6 and IL-8. Concentration of IL-6 and IL-8 release from noninfected ﬁbroblast
(constitutive release), UVi-RV-(UVi-) or RV-16-infected ﬁbroblasts (RV) (MOI = 0.1), highest concentration of vehicle (0.1% DMSO) and
RV infected ﬁbroblasts in the presence of 10
−8–10
−6 MB A Y( n = 10) and DMF (n = 9) measured 48hrs post infection by ELISA. All IL-6
and IL-8 concentrations were compared to their respective RV-induced values (in the absence of drug and vehicle), using a 1-way ANOVA.
All data are presented as mean ±SEM. Signiﬁcance is represented as ∗∗P<0.01 and ∗∗∗P<0.0001.
IL-29 (2 members of the interferon-λ family) and found
that RV infection of primary human ﬁbroblasts does not
induce interferon-λ above the level of constitutive release.
This indicates that the production of interferons in response
to RV is cell type speciﬁc, and our results are similar to other
ﬁndings that showed RV does not induce interferon β in
primary human ﬁbroblasts [18], supporting their hypothesis
that this susceptibility to RV infection may cause ﬁbroblasts
to act as reservoirs for RV replication and spread to the lower
airways.
Toll-like (TLR) receptors are a class of receptors which
recognisedistinctmolecularpatternsthataresharedbypath-
ogens but not by the host. RV is a single-stranded RNA
virus, which in theory could be detected by both TLR 7/8
(single-strandedRNA)andTLR3(double-strandedRNA)as
replicationoccurs.InﬁbroblaststhemechanismbywhichRV
induces cytokines is not known. In our experiments UVi-RV
did not induce cytokines, suggesting that cytokine induction
is replication dependent (i.e., the cell is detecting and
respondingtodouble-strandedRNA).Similarly,inbronchial
epithelial cells, RV induces cytokines via the activation of
TLR-3 and not TLR 7/8 [19] .H o w e v e r ,t h i sr e s p o n s ei sl i k e l y
speciﬁc to RV as in our previous studies we have shown
that ﬁbroblasts respond to agonists of TLR-3 and TLR 7 and
8[ 20]. TLR signalling pathways have not been extensively
studied in lung ﬁbroblasts; however, their activation leads to8 Journal of Allergy
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Figure 4: Eﬀect of DMF on RV replication. Concentration of
virus from RV-infected ﬁbroblasts ± vehicle (0.1% DMSO); or
10
−8–10
−6 MD M F( n = 14) was measured 24hrs post infection
by RV titration. All RV concentrations were compared to RV
concentration in the absence of drug and vehicle by 1-way ANOVA.
All data are presented as mean ±SEM. Signiﬁcance is represented as
∗P<0.05 and ∗∗P<0.01.
downstream activation of transcription factors such as NF-
κB, and this results in the upregulation and induction of
various inﬂammatory cytokines such as IL-6 and IL-8 [21].
The study showed that, at a concentration of 10−10 M,
ﬂuticasone inhibited both RV-induced IL-6 and IL-8, while
dexamethasone inhibited only IL-6. Fluticasone is a more
potent corticosteroid in inhibiting inﬂammation [22], and
our data reﬂect this fact. It is also interesting to note that,
although IL-8 is released more abundantly than IL-6 [23],
this selective inhibition suggests that IL-8 may at least in
part be steroid insensitive, and other studies have also
demonstrated that certain cytokines are steroid insensitive
[24, 25]. Nevertheless, to our knowledge this study is the
ﬁrst to report of RV-induced IL-6 and IL-8 inhibition by
corticosteroids in primary airway ﬁbroblasts and conﬁrms
previous studies demonstrating that corticosteroids inhibits
RV-induced cytokines [7, 26].
The major function of both long- and short-acting β2
agonists in the treatment of asthma is to maintain or to
induce airway relaxation. β2 adrenoceptors are present on
lung ﬁbroblasts as well as airway smooth muscle (ASM);
therefore, β2 agonists may aﬀect ﬁbroblast activities [27].
Previous studies have produced conﬂicting results in regards
to the eﬀects of β2 agonists on cytokine induction in various
airway cells. β2 agonists increased the secretion of TNF-α-
and TGF-β-induced IL-6 in ASM, had no eﬀect on RV-
induced IL-8 in bronchial epithelial cells, and inhibited IL-4
in human peripheral blood mononuclear cells and inhibited
cytokine-induced adhesion molecule expressions, such as
ICAM-1 in human lung ﬁbroblasts [25–31]. This suggests
that β2 agonists in vitro can have positive, neutral, or even
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Figure 5: Salmeterol + ﬂuticasone (Sal + Flut) and Sal + Flut +
BAY inhibit RV-induced IL-6: the amount of IL-6 induced from
ﬁbroblasts infected with RV-16 (MOI = 0.1) was expressed as
100%. Inhibition caused by drug combinations, Sal + Flut (10
−8 +
10
−10 M) and Sal + Flut + BAY (10
−8 +1 0
−10 +1 0
−6 M) (for all
n = 4) was measured 48hrs post infection by ELISA and expressed
as a percentage of RV-induced IL-6. Percentage inhibition caused
by drugs was compared using 1-way ANOVA with RV-induced IL-
6. All data are presented as mean±SEM. Signiﬁcance is represented
as ∗∗P<0.01.
negative eﬀect on cytokine induction in various airway cells
and that the eﬀects of β2 agonists may be stimulus and cell
type dependent. The current study showed for the ﬁrst time
that β2 agonists further increased RV-induced IL-6 and IL-8.
The mechanism by which β2 agonists increase inﬂammation
maybeexplainedbytheirmechanismofactionatthecellular
level. β2 agonists stimulate the β2 adrenoceptor and activate
adenyl cyclase which gives rise to an increase in intracellular
cAMP levels which binds to the cAMP responsive element
binding protein (CREB) in the promoter region of genes and
can result in upregulation of various genes [29]. Since RV
infection alone induces cytokines, the use of β2 agonists may
result in a second signal to further induce proinﬂammatory
cytokines.
Despite their inﬂammatory modulatory capacity, neither
corticosteroids nor β2 agonists aﬀe c t e dR Vr e p l i c a t i o na n d
this suggests that RV replication may not be dependent on
RV-induced inﬂammation. However in vivo studies have
shown that intranasal use of corticosteroids increased and
prolonged RV number and shedding which may be due to
the presence of the immune system [32].
There is good evidence suggesting that RV-induced
inﬂammation is due to NF-κBa c t i v a t i o n[ 6, 33]. For this
reason, this study is the ﬁrst to have examined the eﬀects
of inhibiting NF-κB on RV-induced IL-6 and IL-8 and RV
replication.
BAY inhibits NF-κB by inhibiting IκB-α phosphorylation
[34]. The study showed that BAY inhibited RV-induced IL-
6 but not IL-8 and this was unexpected as previous studies
found that transcription of IL-6 and IL-8 is regulated by
the same transcription factors: NF-κB, AP-1, CREB protein,
and CCAAT/enhancer binding protein (C/EBP) [25, 35].Journal of Allergy 9
Although transcription of IL-8 is mediated by the same tran-
scription factors as IL-6, although IL-8 is partially regulated
by NF-κB, it may be more dominantly or synergistically
regulated by other transcription factors such as AP-1 or
C/EBP and hence explains the result [16, 36]. This study
showedthattheinhibitoryeﬀectsofBAYonRV-inducedIL-6
and IL-8 were not as eﬀective as the corticosteroids.
DMF inhibits the translocation and partially inhibits
the transactivation of NF-κB but does not inhibit NF-κB
completely [37]. In our study, DMF had no eﬀect on RV-
induced IL-6 and IL-8 but increased RV replication. The
increase in replication may be an example of how some
viruses can exploit NF-κB for their own replication and
survival [8]. Most viruses that induce NF-κBa c t i v i t yo f t e n
harbour NF-κB binding elements in their viral promoters
and therefore would have a replicative advantage if there is
active NF-κB in the cytoplasm [8, 38]. One example of this is
the low-level NF-κB activation by HIV-1 which allows HIV-1
tomaintainachronicinfectioninmyeloidcells[38].Byusing
the basic local alignment search tool (BLAST) we found that
thereareafewNF-κBbindingmotifsontheRVgenome[39].
Although we cannot conﬁrm whether these binding motifs
can actively bind NF-κB and produce a functional outcome,
if they are true it may be possible that RV-16 may be utilising
a similar process to HIV-1. Alternatively, DMF may have
other properties which may be delaying cellular apoptosis
and therefore allowing increased replication to occur [40],
both, which require further investigation.
These results suggest that NF-κB activation alone may
not be the factor that results in RV-induced inﬂammation
but perhaps a combined activation of NF-κB, AP-1 and
C/EBP, and alternative inhibitors of these transcription
factors should be examined.
This study also examined whether the commonly used
corticosteroid and β2 agonist combination therapy in the
treatment of asthma could aﬀect RV-induced IL-6 and RV
replication. Our study showed that ﬂuticasone inhibited IL-
6 production (100%) in response to RV infection, whilst
salmeterol increased RV-induced IL-6 production. How-
ever when used together suppression of RV-induced IL-6
occurred (80%), reﬂecting similar results to Edwards et al.,
[2] showing the same combination inhibiting RV-induced
IL-8 from bronchial epithelial cells. The addition of the
NF-κB inhibitor BAY to this combination suppressed RV-
induced IL-6 further (100%). Despite neither combination
altering RV replication, the results were as expected, as
earlier we established that both BAY and ﬂuticasone were
potent inhibitors of RV-induced IL-6, and this combined
result shows the additive inhibitory eﬀect of these drugs.
These ﬁndings suggest that during RV-induced asthma
exacerbations, the use of combination therapy may not be
as useful as corticosteroids alone, but may still be beneﬁcial.
Furthermore, it is possible that incorporating a NF-κB
inhibitor into this combination may make the combined
therapy more eﬀective for the treatment of both asthma and
RV-induced asthma exacerbations.
This study albeit in vitro suggests that in the event of
RV-induced asthma exacerbation, asthma steroidal medi-
cation alone is more beneﬁcial in inhibiting RV-induced
inﬂammation than β2 agonists. In reality this is unrealistic
as β2 agonists are required to provide bronchorelaxation
duringRV-inducedasthmaexacerbations.Thereforeperhaps
alternative bronchodilators such as anticholinergics could
be used during a viral exacerbation. Furthermore, NF-
κB inhibitors are not as eﬀective as corticosteroids and
may be detrimental if used incorrectly. In conclusion, NF-
κB inhibitors remain a potential therapeutic treatment for
RV-induced asthma exacerbation; however, future research
into drug combinations such as corticosteroids and NF-κB
inhibitors, multiple NF-κB inhibitors or inhibitors of other
transcription factors such as AP-1 and C/EBP may pave the
way for more therapeutic options.
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